Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...

The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 ...

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to treat chronic spontaneous urticaria in patients 12 years and older whose hives ...

While severe pain and burning are typical symptoms, tingling and buzzing sensations, along with numbness, can also be early ...

A 43-year-old woman presented with 6 months of recurrent bilateral eye pain and redness alongside spontaneous urticaria.She ...

Understanding the causes, symptoms, treatment options, and why urticaria may worsen at night is essential for effective management. Urticaria is an inflammatory skin disorder. According to the ...

The skin comes in contact with a normally harmless substance that the ... There is evidence that treating the thyroid condition may also improve urticaria symptoms. If your urticaria is related to an ...